Drug intelligence / Profile preview

124I-hJAA-F11

Development stage: Discontinued
Lead developer: Roswell Park Comprehensive Cancer Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

124I-hJAA-F11 is an investigational radiopharmaceutical designed for positron emission tomography (PET) imaging of solid tumors. It consists of the humanized monoclonal antibody hJAA-F11 conjugated to the positron-emitting isotope iodine-124 (124I). The antibody component specifically targets the Thomsen-Friedenreich antigen (TF-Ag), a tumor-associated carbohydrate antigen (Gal-beta-1,3-GalNAc-alpha-O-Ser/Thr) that is expressed in over 90% of lung, breast, and prostate cancers but is virtually absent in normal tissues. By binding to TF-Ag-expressing cells, the agent allows for the non-invasive visualization and localization of malignant lesions via PET/CT scanning. This molecular imaging tool is primarily being evaluated for its diagnostic efficacy and potential as a companion diagnostic for TF-Ag-targeted therapies.

Other names: Iodine I 124 humanized monoclonal antibody hJAA-F11Iodine 124-hJAA-F11Iodine124-hJAA-F11Iodine-124-hJAA-F11124I-labeled hJAA-F11

Targets

TF antigen (Thomsen-Friedenreich antigen)

Beyond the preview

Go deeper on 124I-hJAA-F11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 124I-hJAA-F11.

Explore the full profile